Medivation Inc (MDVN)

pos +0.00
Today's Range: 106.59 - 109.75 | MDVN Avg Daily Volume: 1,092,900
Last Update: 01/30/15 - 3:59 PM EST
Volume: 0
YTD Performance: 9.25%
Open: $0.00
Previous Close: $107.94
52 Week Range: $54.37 - $117.23
Oustanding Shares: 77,624,659
Market Cap: 8,378,805,692
6-Month Chart
TheStreet Ratings Grade for MDVN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 12 11 10 10
Moderate Buy 0 0 0 0
Hold 3 2 2 2
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 1.63 1.57 1.62 1.62
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 76.01
Price Earnings Comparisons:
MDVN Sector Avg. S&P 500
76.01 76.30 25.69
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
5.92% 34.13% 296.65%
Revenue 50.20 3.37 0.63
Net Income 0.00 0.25 0.00
EPS 0.00 0.14 0.00
Earnings for MDVN:
Revenue 0.27B
Average Earnings Estimates
Qtr (12/14) Qtr (03/15) FY (12/14) FY (12/15)
Average Estimate $1.21 $0.36 $2.59 $3.55
Number of Analysts 7 3 8 8
High Estimate $1.66 $0.72 $3.11 $5.51
Low Estimate $1.03 $0.17 $2.38 $2.28
Prior Year $0.03 $-0.18 $-0.57 $2.59
Growth Rate (Year over Year) 3,928.57% 301.85% 553.73% 37.07%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
It's the only way to deal with this market.
Sep 24, 2014 | 6:45 AM EDT
MDVN was downgraded from Buy to Neutral, Goldman Sachs said. Valuation call, based on a $110 price target.
Sep 18, 2014 | 7:20 AM EDT
MDVN was upgraded to Buy, Canaccord Genuity said. $132 price target. Company is gaining market share in the pre-chemotherapy market.&nb...

An Indication of Weakness Real Money Pro($)

Consider going short if you aren't already.
Sep 09, 2014 | 8:12 AM EDT
MDVN was upgraded from Market Perform to Outperform, Bernstein said. $118 price target. Prevail should drive growth. 
Mar 03, 2014 | 7:49 AM EST
MDVN lowered its numbers, UBS said. Driven by disappointing Xtandi guidance. $85 price target and Buy rating, 
Feb 03, 2014 | 7:36 AM EST
MDVN was downgraded from Buy to Hold, Needham said. Valuation call.   
Jan 29, 2014 | 7:31 AM EST
MDVN raised its price target and estimates through 2015, UBS said. Better-than-expected full PREVAIL data, appearing favorably vs Zytig...
Jul 17, 2013 | 7:57 AM EDT
MDVN was upgraded to Buy from Neutral and given a $74 price target, said UBS. The upgrade comes ahead of the ph3 PREVAIL study.
Mar 04, 2013 | 7:09 AM EST
MDVN was initiated with a Buy rating, Needham said. Xtandi is rapidly gaiing market share for the treatment of prostate cancer.   ...

Columnist Conversations

As Super Bowl XLIX approaches and you are getting ready to watch the game, we leave you with a financial stati...
To add to Jim's column (posted to the left)... Another concern that has recently developed is that the enormou...
The collapse in stock prices in the last two hours of Friday's session created another round of sinister dark ...
It's been a while since I have shown this chart. For the last 2 years the yields on the Five Year Note have tr...


Columnist Tweets


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.